Beam Therapeutics (BEAM) Projected to Post Quarterly Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.11) per share and revenue of $14.69 million for the quarter.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.16. The firm had revenue of $30.00 million for the quarter, compared to analyst estimates of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The business’s quarterly revenue was down 90.5% compared to the same quarter last year. During the same period last year, the company earned $1.73 EPS. On average, analysts expect Beam Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Beam Therapeutics Stock Up 2.1 %

BEAM stock opened at $20.24 on Friday. Beam Therapeutics has a twelve month low of $13.53 and a twelve month high of $35.25. The company has a market cap of $2.04 billion, a P/E ratio of -11.50 and a beta of 2.35. The business has a fifty day moving average of $21.00 and a 200-day moving average of $24.54.

Insider Buying and Selling

In related news, President Giuseppe Ciaramella sold 7,434 shares of Beam Therapeutics stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total value of $136,413.90. Following the sale, the president now owns 190,216 shares of the company’s stock, valued at approximately $3,490,463.60. This trade represents a 3.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John M. Evans sold 30,663 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total value of $562,666.05. Following the transaction, the chief executive officer now directly owns 986,249 shares of the company’s stock, valued at approximately $18,097,669.15. This trade represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 43,771 shares of company stock valued at $803,198. 4.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BEAM. Cantor Fitzgerald restated an “overweight” rating on shares of Beam Therapeutics in a research report on Wednesday, March 12th. Jones Trading raised shares of Beam Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective on the stock in a research note on Monday, March 10th. Wedbush reiterated an “outperform” rating and set a $57.00 target price on shares of Beam Therapeutics in a research report on Monday, March 10th. Scotiabank raised Beam Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $40.00 price objective for the company in a research note on Monday, March 10th. Finally, Sanford C. Bernstein raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Beam Therapeutics has an average rating of “Buy” and a consensus price target of $49.45.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.